Xinolax DR 30 mg (Capsule (Delayed Release))

Title

Categories

• Serotonin-norepinephrine reuptake inhibitor (SNRI)

Description

Dimensions

Color Options

Functions

• Treatment of Major Depressive Disorder (MDD)
• Treatment of Generalized Anxiety Disorder (GAD)
• Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
• Treatment of Fibromyalgia
• Treatment of Chronic Musculoskeletal Pain

Materials

Technical Specifications

• Duloxetine Hydrochloride as active ingredient
• Selective serotonin and norepinephrine reuptake inhibitor (SSNRI)
• Inhibits dopamine reuptake
• No significant affinity for various receptors
• Well absorbed when orally administered
• Metabolized mainly through hepatic metabolism

Design Elements

Usability Features

Dosage

• Starting Dose for MDD: 40 mg/day to 60 mg/day
• Target Dose for MDD: Acute - 40 mg/day to 60 mg/day; Maintenance - 60 mg/day
• Maximum Dose for MDD: 120 mg/day
• Starting Dose for GAD: 60 mg/day
• Target Dose for GAD: 60 mg/day
• Maximum Dose for GAD: 120 mg/day
• Starting Dose for DPNP: 60 mg/day
• Target Dose for DPNP: 60 mg/day
• Maximum Dose for DPNP: 60 mg/day
• Starting Dose for Fibromyalgia: 30 mg/day
• Target Dose for Fibromyalgia: 60 mg/day
• Maximum Dose for Fibromyalgia: 60 mg/day
• Starting Dose for Chronic Musculoskeletal Pain: 30 mg/day
• Target Dose for Chronic Musculoskeletal Pain: 60 mg/day
• Maximum Dose for Chronic Musculoskeletal Pain: 60 mg/day
• Some patients may benefit from starting at 30 mg once daily
• No evidence that doses greater than 60 mg/day confers an additional benefit
• Gradual dose reduction is recommended to avoid discontinuation symptoms

Interaction

• Metabolism affected by CYP1A2 and CYP2D6 isozymes
• Inhibited by fluvoxamine, cimetidine, and quinolone antimicrobials
• Concomitant use with potent CYP2D6 inhibitors may increase concentrations

Contraindications

• Known hypersensitivity to Duloxetine or inactive ingredients
• Not approved for treating bipolar depression
• Not for patients with substantial alcohol use or chronic liver disease
• Use cautiously in patients with controlled narrow-angle glaucoma

Side Effects

• Nausea
• Dizziness
• Dry mouth
• Constipation
• Decreased appetite
• Fatigue
• Somnolence
• Increased sweating
• Hyperhidrosis
• Asthenia
• Slightly increases blood pressure
• No clinically significant differences observed for cardiac intervals

Pregnancy & Lactation

• Pregnancy Category C
• Use during pregnancy only if benefit justifies potential risk to fetus
• Effect on labor and delivery in humans is unknown
• Use during labor and delivery only if benefit justifies potential risk to fetus
• Unknown whether excreted into human milk, not recommended for nursing

Precautions & Warnings

• Patients treated with antidepressants should be monitored for clinical worsening and suicidality
• Blood pressure should be measured before and during treatment
• Caution about bleeding risk with concomitant use of NSAIDs, aspirin, or other coagulation-affecting drugs
• Use cautiously in patients with a history of mania or seizure disorder

Use in Special Populations

• Safety and efficacy in pediatric patients not established

Overdose Effects

• Limited clinical experience with overdose in humans
• No specific antidote
• Treatment should consist of general measures for overdose management
• Emesis induction not recommended
• Gastric lavage with appropriate airway protection may be indicated if performed soon after ingestion or in symptomatic patients
• Activated charcoal may be useful in limiting absorption

Storage Conditions

• Do not store above 30°C
• Keep away from light and out of the reach of children

Related Brands

• Duloxen 60 mg (Tablet (Delayed Release)) - incepta-pharmaceuticals-ltd
• Diliner DR 20 mg (Capsule (Delayed Release)) - square-pharmaceuticals-plc
• Deloxi 60 mg (Capsule (Delayed Release)) - eskayef-pharmaceuticals-ltd
• Deloxi 20 mg (Capsule (Delayed Release)) - eskayef-pharmaceuticals-ltd
• Stresin 30 mg (Capsule (Delayed Release)) - unimed-unihealth-pharmaceuticals-ltd